Syndromic vs non syndromic deafness short note
Reading File
Now let me search the medical library for content on syndromic and non-syndromic deafness in parallel.
Finding Sources
Finding Sources
Searching PubMed
"syndromic" AND "non-syndromic" AND "hearing loss"
Good, found relevant sections. Let me read the key textbook blocks in parallel.
Reading File
Reading File
Reading File
Excellent content retrieved. Let me also get the section on syndromic hearing loss and more details on specific syndromes.
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
I now have excellent content from multiple authoritative textbooks. Let me compile the comprehensive answer.
Syndromic vs Non-Syndromic Deafness
Overview
Hearing loss with a genetic basis can be broadly divided into two categories based on whether the deafness occurs in isolation or as part of a larger clinical syndrome.
Non-Syndromic Hearing Loss (NSHL)
Definition: Sensorineural hearing loss (SNHL) that occurs without any additional manifestations in at least one other body system. It accounts for approximately 70% of all genetic SNHL, making it by far the more common category.
- Scott-Brown's Otorhinolaryngology, Vol 2
Inheritance Patterns
| Mode | Proportion of NSHL |
|---|---|
| Autosomal Recessive (AR) | ~80% |
| Autosomal Dominant (AD) | ~15-18% |
| X-linked | ~1% |
| Mitochondrial | ~1% |
Gene Nomenclature (DFN Loci)
Gene loci for non-syndromic deafness are designated DFN (DeaFNess):
- DFNA - Autosomal Dominant
- DFNB - Autosomal Recessive
- DFNX - X-linked
The number after the prefix reflects the order of gene discovery (e.g., DFNB1, DFNA2, etc.).
Key Genes
1. GJB2 (Connexin 26) - DFNB1:
- The single most important hearing impairment gene
- Located at the DFNB1 locus
- Responsible for >50% of recessive NSHL and approximately 30-50% of all innate (congenital) hearing loss
- The 35delG mutation accounts for ~70% of all GJB2 mutations worldwide
- 167delT is the most frequent mutation in Ashkenazi Jews
- Over 300 mutations documented; nearly 50% of all non-syndromic hearing loss traces back to connexin 26
2. Other Connexin Genes: CX30 (GJB6), CX31 (GJB3)
3. Myosin genes: MYO1A, MYO3A, MYO6, MYO7A, MYO15A (unconventional myosins expressed in hair cells)
4. Other protein families: Adhesion proteins, ion channels, transcription factors (>100 NSHI loci identified so far)
Clinical Features of AR vs AD NSHL
| Feature | AR NSHL (DFNB) | AD NSHL (DFNA) |
|---|---|---|
| Onset | Prelingual (congenital/early childhood) | Usually postlingual |
| Progression | Stable or slowly progressive | Usually progressive |
| Severity | Severe to profound | Moderate, progressive |
| Family history | Horizontal (affected siblings) | Vertical (multiple generations) |
Note: Exceptions exist - some AD loci (e.g., TECTA - DFNA8/12) cause prelingual loss.
- Scott-Brown's, Vol 2; Scott-Brown's, Vol 1
Syndromic Hearing Loss
Definition: Hearing loss that occurs as part of a recognizable syndrome with features in at least one other organ system. Accounts for approximately 30% of all genetic hearing loss, with over 400 syndromes known to be associated.
- Scott-Brown's Otorhinolaryngology, Vol 2
Common Syndromes - Summary Table
| Syndrome | Inheritance | Hearing Loss Type | Associated Features |
|---|---|---|---|
| Pendred | AR | SNHL (progressive, high-frequency) | Goitre (develops in early puberty/adulthood), widened vestibular aqueducts, enlarged endolymphatic sac; gene: SLC26A4 (pendrin) |
| Usher | AR | SNHL (severe-profound) | Retinitis pigmentosa, vestibular dysfunction; MYO7A mutation in type 1B |
| Jervell and Lange-Nielsen | AR | Profound bilateral SNHL | Long QT syndrome, risk of sudden cardiac death |
| Waardenburg | AD | SNHL (congenital) | White forelock, heterochromia iridis, dystopia canthorum, patches of depigmented skin; PAX3 mutations (WS1/2); MITF mutations (WS2/Tietz) |
| Branchio-Oto-Renal (BOR) | AD | Mixed or SNHL | Branchial cleft anomalies, preauricular pits, renal anomalies |
| Stickler | AD | SNHL + conductive | Cleft palate, myopia, retinal detachment, arthropathy |
| Neurofibromatosis Type 2 (NF2) | AD | Progressive SNHL | Bilateral vestibular schwannomas (presents in childhood/young adult) |
| Treacher Collins | AD | Conductive | Mandibulofacial dysostosis, malar hypoplasia, microtia, choanal atresia |
| CHARGE | Sporadic/AD | Mixed | Coloboma, Heart defects, Atresia choanae, Restricted growth, Genital anomalies, Ear anomalies |
- Scott-Brown's ORL, Vol 1 & Vol 2; Fitzpatrick's Dermatology
Key Differences at a Glance
| Feature | Non-Syndromic | Syndromic |
|---|---|---|
| Proportion of genetic deafness | ~70% | ~30% |
| Other organ involvement | None | Yes (defining feature) |
| Number of syndromes/loci | >100 loci | >400 syndromes |
| Most common gene | GJB2 (Connexin 26) | Varies (SLC26A4, MYO7A, PAX3, etc.) |
| Most common inheritance | AR | Both AR and AD, depends on syndrome |
| Diagnosis | Molecular genetics / gene panel | Clinical + molecular |
Clinical Approach
- History and clinical exam - look for features in other systems (eyes, skin, thyroid, cardiac, renal, skeletal)
- Audiogram - type (SNHL vs conductive vs mixed), onset, progression
- Imaging - CT/MRI temporal bones (enlarged vestibular aqueduct in Pendred, cochlear aplasia/hypoplasia)
- ECG - rule out Jervell-Lange-Nielsen (prolonged QT)
- Ophthalmology - rule out Usher (retinitis pigmentosa) and Stickler (myopia, retinal detachment)
- Genetic testing - GJB2/GJB6 sequencing first (most common), then hearing loss gene panel if negative
- Thyroid function - for Pendred syndrome
A multidisciplinary team including audiologist, otolaryngologist, and clinical geneticist is recommended for evaluation.
- Scott-Brown's Otorhinolaryngology, Vol 2
Recent evidence note: A 2025 meta-analysis (PMID: 39970981) examined the global prevalence of mitochondrial MT-RNR1 A1555G variant in non-syndromic hearing loss, and a 2025 systematic review (PMID: 39862573) analyzed pathogenic GJB2 variants in the Asian population - both confirming continued genetic heterogeneity in NSHL. Waardenburg syndrome genetics in Africa were also systematically reviewed in 2025 (PMID: 41516007), reaffirming the important role of PAX3/MITF mutations.
This is a shared conversation. Sign in to Orris to start your own chat.